Evaluation of the Efficacy and Safety of Insulin Detemir Compared With That of NPH Insulin in Subjects With Type 1 Diabetes.

Inclusion Criteria: * Signed and dated informed consent obtained before any trial-related activities * Type 1 diabetes diagnosed and classified according to aetiology * Duration of type 1 diabetes equal to or more than 12 months * Glycosylated haemoglobin less than or equal to 12 percent based on analysis from central laboratory * Able and willing to perform self-blood glucose monitoring Exclusion Criteria: * Proliferative retinopathy * Total basal insulin dose of more than 100 IU per day * Recurrent major hypoglycaemia - that would interfere with trial participation (as judged by the investigator) * Known unawareness of hypoglycaemia * Previous treatment with insulin detemir